Biochemical aspects of arrhythmogenesis and ventricular fibrillation.
D000200:Action Potentials; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D003994:Bucladesine; D002395:Catecholamines / Q000378:metabolism* / Q000502:physiology; D000242:Cyclic AMP / Q000378:metabolism* / Q000502:physiology; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D006019:Glycolysis; D006801:Humans; D006947:Hyperkalemia / Q000150:complications; D007773:Lactates / Q000097:blood*; D008564:Membrane Potentials; D009203:Myocardial Infarction / Q000150:complications*; D009206:Myocardium / Q000378:metabolism*; D011188:Potassium / Q000378:metabolism*; D011690:Purkinje Fibers / Q000503:physiopathology; D013806:Theophylline; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002395:Catecholamines; D005230:Fatty Acids, Nonesterified; D007773:Lactates; D003994:Bucladesine; D013806:Theophylline; D000242:Cyclic AMP; D011188:Potassium